DANBURY, Conn., July 16 /PRNewswire-FirstCall/ -- Biodel Inc. NASDAQ: BIOD today announced that its two pivotal Phase III VIAject(TM) clinical trials are now complete, with the last study patient visit on July 14, 2008. Results of the full trial will be released either at Biodel's poster presentation at the European Association for the Study of Diabetes (EASD) on Tuesday, September 9, 2008, or at a later appropriate scientific forum.
More at:
http://sev.prnewswire.com/health-care-hospitals/20080716/NYW13316072008-1.html
Posts
No comments :
Post a Comment